

## Institutions contributing to the pilots

### France

- French Health Products Safety Agency (AFSSAPS)
- Economic Committee on Health Care Products (CEPS)
- French National Authority for Health (HAS)
- Transparency Commission

### Germany

- Federal Institute for Drugs and Medical Devices (BfArM)
- Federal Joint Committee (G-BA)
- Paul Ehrlich Institute (Observer)

### Italy

- Italian Medicines Agency (AIFA)

### The Netherlands

- College of Health Insurances (CVZ)
- Dutch Diabetes Association
- Netherlands Breast Cancer Association (BVN)
- Menzis
- Netherlands Insurance Company (UVIT)

### Sweden

- Medical Products Agency (MPA)
- Swedish Association of Local Authorities and Regions (SKL)
- Swedish Breast Cancer Association (BRO)
- Dental and Pharmaceutical Benefits Board (TLV)

### United Kingdom

- Medicines and Healthcare Products Regulatory Agency (MHRA)
- National Institute for Health and Clinical Excellence (NICE)
- National Health Service primary care trusts (Derbyshire County, Redcar & Cleveland, Stockton-on-Tees)

*continued overleaf*

**Europe**

- European Medicines Agency (EMA)
- European Network for Health Technology Assessment (EUnetHTA) (*observer*)
- EUROPA DONNA, the European Breast Cancer Coalition (*observer*)

**United States**

- Food and Drug Administration (*liaison*)

**Industry**

- AstraZeneca
- Bristol-Myers Squibb
- GlaxoSmithKline
- Janssen Pharmaceutical Companies of Johnson & Johnson